Despite the exciting clinical progression of protein degradation therapies, much of the fundamental biology and chemistry in the field is still unknown, with many discovery and development challenges still holding back the translation of robust candidates into the clinic.

The Inaugural Targeted Protein Degradation (TPD) Europe 2020, as your forward looking and industry dedicated platform, will be bringing together key European and international experts in the field of protein degradation to capture the most pioneering data, thought provoking insights and practical lessons learned, enabling you to maximise the therapeutic window of your protein degradation strategy.

Built with large pharma and biotech insight, TPD Europe 2020 focuses on expanding the fundamental understanding of protein degradation in order to validate the next generation of druggable targets, optimise drug-like properties and leverage degradation pathways beyond the ubiquitin-proteasome system to accelerate robust translation of protein degradation candidates for clinical trials in oncology and neurodegenerative diseases.

View the full event guide for further details on speakers, content and how to join those who are re-defining the targeted protein degradation field.

Day
Hour
Minute
Second

TPD Europe 2020 Confimed Attendees Include:

Amgen
xc
logo243
astrazeneca
1200px-Bayer_Logo.svg
dddddddd
1200px-Chugai_Pharmaceutical.svg
1200px-Evotec.svg
download (1)
download (2)
Merck-1440x960
Sanofi
download (2)
Vernalis Therapeutics Inc. (PRNewsFoto/Vernalis Therapeutics, Inc.)

Snapshot of Our World Class Speaker Faculty

Alessio Ciulli

Professor of Structural Chemical Biology

University of Dundee

Georg Winter

Principal Investigator

CeMM Research Centre for Molecular Medicine

John Harling

Senior Scientific Director of Medicinal Chemistry

GlaxoSmithKline

Randy Teel

Vice President of Corporate Development

Arvinas

Bomie Han

Research Advisor

Eli Lilly

Diala Ezzeddine

Chief Executive Officer

Xios Therapeutics

Laura Luh

Research Scientist

Bayer AG

Nello Mainolfi

Founder, President & Chief Scientific Officer

Kymera Therapeutics

Confirmed Partners 2020

admin-ajax
先导LOGO
download (1)
download
Proteome-Sciences-Plc
Logo
NanoTemper-logo-stacked

Media Partners 2020

Capture

Other Events In The Undruggable Series